← Search & browse all drugs

pyrrobutamine, combinations

R06AX58

Forms & Strengths

Combination oral tablets: pyrrobutamine phosphate combined with sympathomimetics (e.g., pseudoephedrine) and/or antihistamines/analgesics.

Adult Dosing

1 tablet orally every 6 to 8 hours as needed for allergic rhinitis symptoms.
Do not exceed maximum daily doses specified by specific combination product labeling.

Pediatric Dosing

Safety and efficacy not established in children under 12 years of age for combination formulations containing pyrrobutamine; consult specific product labeling for older adolescents.

Indications

Symptomatic relief of allergic rhinitis, upper respiratory allergies, and associated nasal congestion.

Mechanism of Action

Pyrrobutamine acts as a competitive histamine H1-receptor antagonist, reducing allergic symptoms.
Combined sympathomimetic agents (e.g., pseudoephedrine) act as alpha-adrenergic agonists, causing nasal mucosal vasoconstriction.

Contraindications

Hypersensitivity to pyrrobutamine or any component of the formulation.
Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation.
Severe hypertension or severe coronary artery disease (when combined with sympathomimetics).

Adverse Reactions

Drowsiness, sedation, and fatigue.
Anticholinergic effects: dry mouth, blurred vision, urinary retention, and constipation.
Central nervous system stimulation, insomnia, tachycardia, and palpitations (primarily related to sympathomimetic components).

Drug Interactions

Central nervous system depressants (alcohol, sedatives, tranquilizers) may potentiate sedative effects.
Monoamine oxidase inhibitors (MAOIs) may lead to hypertensive crises and severe adverse cardiovascular events.
Other sympathomimetic agents may increase the risk of additive cardiovascular toxicity and elevated blood pressure.

Curated Content: Needs Vetting Before Put to Clinical Use